Adaptimmune Therapeutics PLC — Director's Dealing 2017

Mar 15, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2017-03-15

Reporting Person: Bertrand William C JR (Chief Operating Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.79	2027-03-15	Ordinary Shares (3407904)		Direct

Footnotes

F1: Exercisable as to 851,976 Ordinary Shares on March 15, 2018 and will be exercisable as to the remainder in monthly installments of 70,998 Ordinary Shares on the fifteenth of each month from April 15, 2018 through March 15, 2021.

F2: The exercise price was converted from GBP0.65 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.